About the Editor:
Dr. Sylvie Blondelle is an Associate Member in Microbiology/Biochemistry at Mixture Science, Inc., San Diego, CA and Head of the Biosafety Department at the Burnham Institute for Medical Research. Her research focuses on strategies toward the development an HIV vaccine through optimization of peptide immunogens. Dr. Blondelle received her Ph.D. in organic chemistry from the University of Montpellier, France, in 1988.
This second completely updated and revised edition of Volume VI of The Mycota consists of state of the art reviews written by experts in the field, covering three major areas of this rapidly developing field. In the first part the current understanding of pathogenic fungi and the physiological reactions relevant for the pathogen - host interaction are elucidated. The second part describes novel technologies for the identification of proteins, virulence factors and mechanisms central to the host - pathogen interaction. The third part deals with the characterization of the host response towards pathogenic fungi and addresses timely clinical aspects.
This volume focuses on the role of DCs in the pathogenesis and immunity of HIV-1 infection. It has recently been clarified that DCs are important targets and reservoirs of HIV and may play an important role in virus spreading to T cells. Interestingly, HIV can exploit many of the cellular processes responsible for the generation and regulation of the adaptive immune responses to gain access to its main target cells, i.e. the CD4+ T lymphocytes. Thus, the central role of DCs in stimulating T cell activation not only provides a route for viral transmission, but also represents a vulnerable point at which HIV-1 can interfere with the initiation of primary T cell immunity.
Recent studies have revealed that several HIV proteins can profoundly influence the phenotype and functions of DCs even in the absence of a productive infection, often resulting in an abnormal immune response. While this knowledge has resulted in the identification of some major mechanisms involved in the pathogenesis of HIV-1 infection, the recent progress on DC biology has opened perspectives in the research on new adjuvants (selectively acting on DCs) and on novel strategies for the in vivo targeting of antigens to DCs, which appear to be highly relevant for the development of HIV vaccines. Of note, defects in the number and functions of DCs have been observed in the course of HIV infection and during disease progression, thus suggesting that DCs play an important role in the immune control of viral replication and virus-induced dysfunctions. The development of therapeutic vaccination strategies to be combined with HAART is thought as an important step for an effective control of HIV infection in patients. In this context, the use of autologous DCs may represent an attracting strategy. Notably, DCs are now regarded as a valuable approach for the development of cancer vaccines and several clinical trials have explored the efficacy of different DC preparations as cellular adjuvants in inducing a potentially protective immune response. Recent data in animal models provide the background for the clinical testing of DC-based vaccines in HIV-1-infected patients. Now that we start to understand the complex interactions between HIV and DCs in the pathogenesis of AIDS and we are learning how to prepare potentially effective DCs from lessons on cancer vaccines, we may reasonably assume that DC-based therapeutic vaccines can represent a topic of increasing interest in protocols of clinical immunotherapy of HIV-1-infected patients.